Spots Global Cancer Trial Database for Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Official Title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Study ID: NCT00908752
Conditions
Study Description
Brief Summary: The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Richard Finn, M.D., Los Angeles, California, United States
Sharp Clinical Oncology Research, San Diego, California, United States
Montefiore Medical Center, Bronx, New York, United States
Rhode Island Hospital, Providence, Rhode Island, United States
The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
University Of Virginia Health System, Charlottesville, Virginia, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Local Institution, Capital Federal, Buenos Aires, Argentina
Local Institution, Buenos Aires, , Argentina
Local Institution, Parkville, Victoria, Australia
Local Institution, Vancouver, British Columbia, Canada
Local Institution, Montreal, Quebec, Canada
Local Institution, Beijing, Beijing, China
Local Institution, Guanzhou, Guangdong, China
Local Institution, Nanning, Guangxi, China
Local Institution, Harbin, Heilongjiang, China
Local Institution, Changsha, Hunan, China
Local Institution, Changzhou, Jiangsu, China
Local Institution, Nanjing, Jiangsu, China
Local Institution, Nanjing, Jiangsu, China
Local Institution, Nanjing, Jiangsu, China
Local Institution, Suzhou, Jiangsu, China
Local Institution, Changchun, Jilin, China
Local Institution, Xi'an, Shan3xi, China
Local Institution, Shanghai, Shanghai, China
Local Institution, Shanghai, Shanghai, China
Local Institution, Chengdu, Sichuan, China
Local Institution, Tianjing, Tianjin, China
Local Institution, Hangzhou, Zhejiang, China
Local Institution, Angers, , France
Local Institution, Bondy, , France
Local Institution, Bordeaux, , France
Local Institution, Clichy Cedex, , France
Local Institution, Creteil Cedex, , France
Local Institution, Grenoble, , France
Local Institution, Lille Cedex, , France
Local Institution, Lyon Cedex 04, , France
Local Institution, Marseille Cedex 05, , France
Local Institution, Paris Cedex, , France
Local Institution, Paris, , France
Local Institution, Toulouse Cedex 09, , France
Local Institution, Hong Kong, , Hong Kong
Local Institution, New Territories, , Hong Kong
Local Institution, Genova, , Italy
Local Institution, Padova, , Italy
Local Institution, Pisa, , Italy
Local Institution, Roma, , Italy
Local Institution, Toyoake City, Aichi, Japan
Local Institution, Chiba-shi, Chiba, Japan
Local Institution, Kashiwa-shi, Chiba, Japan
Local Institution, Ogaki-shi, Gifu, Japan
Local Institution, Hiroshima City, Hiroshima, Japan
Local Institution, Kure-shi, Hiroshima, Japan
Local Institution, Sapporo-shi, Hokkaido, Japan
Local Institution, Kanazawa-shi, Ishikawa, Japan
Local Institution, Kawasaki-shi, Kanagawa, Japan
Local Institution, Yokohama, Kanagawa, Japan
Local Institution, Kochi-shi, Kochi, Japan
Local Institution, Kumamoto-shi, Kumamoto, Japan
Local Institution, Kyoto-shi, Kyoto, Japan
Local Institution, Tsu-shi, MIE, Japan
Local Institution, Okayama-shi, Okayama, Japan
Local Institution, Higashinari-ku, Osaka, Japan
Local Institution, Osaka-sayama City, Osaka, Japan
Local Institution, Osaka-shi, Osaka, Japan
Local Institution, Osaka-shi, Osaka, Japan
Local Institution, Osaka-shi, Osaka, Japan
Local Institution, Sunto-gun, Shizuoka, Japan
Local Institution, Chuo-ku, Tokyo, Japan
Local Institution, Minato-ku, Tokyo, Japan
Local Institution, Musashino-shi, Tokyo, Japan
Local Institution, Toyama City, Toyama, Japan
Local Institution, Nishinomiya-shi, , Japan
Local Institution, Busan, , Korea, Republic of
Local Institution, Kyunggi-do, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Suwon, , Korea, Republic of
Local Institution, Taegu, , Korea, Republic of
Local Institution, Madrid, , Spain
Local Institution, Madrid, , Spain
Local Institution, Valencia, , Spain
Local Institution, Valencia, , Spain
Local Institution, Kaohsiung, , Taiwan
Local Institution, Taichung, , Taiwan
Local Institution, Tainan, , Taiwan
Local Institution, Taipei, , Taiwan
Local Institution, Taipei, , Taiwan
Local Institution, Taoyuan, , Taiwan
Local Institution, Bangkok, , Thailand
Local Institution, Bangkok, , Thailand
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
